OAM
SUPN icon

Oppenheimer Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Oppenheimer Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-19
Closed – – 1405
2020
Q1 		$0 Sell
19
-52
-73% -$1.09K ﹤0.01% 1628
2019
Q4 		$2K Hold
71
– – ﹤0.01% 1574
2019
Q3 		$2K Sell
71
-10,296
-99% -$305K ﹤0.01% 1578
2019
Q2 		$343K Sell
10,367
-3,667
-26% -$126K 0.01% 921
2019
Q1 		$491K Sell
14,034
-4,519
-24% -$168K 0.01% 813
2018
Q4 		$616K Buy
18,553
+3,740
+25% +$161K 0.02% 695
2018
Q3 		$746K Buy
14,813
+1,251
+9% +$61.8K 0.02% 701
2018
Q2 		$812K Sell
13,562
-1,679
-11% -$87K 0.02% 654
2018
Q1 		$698K Buy
15,241
+282
+2% +$11.8K 0.02% 692
2017
Q4 		$598K Hold
14,959
– – 0.02% 742
2017
Q3 		$598K Buy
14,959
+4,738
+46% +$205K 0.02% 746
2017
Q2 		$441K Sell
10,221
-620
-6% -$22.1K 0.01% 815
2017
Q1 		$339K Buy
+10,841
New +$291K 0.01% 893

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Oppenheimer Asset Management's SUPN Position: Q2 2020 in Review

Oppenheimer Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 19 shares.

Oppenheimer Asset Management first reported a position in SUPN in Q1 2017 and held it in 13 quarters. The position peaked at $812K in Q2 2018. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

  • Oppenheimer Asset Management reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Oppenheimer Asset Management sold 19 Supernus Pharmaceuticals shares in Q2 2020.
  • Oppenheimer Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 13 quarters.
  • Oppenheimer Asset Management's Supernus Pharmaceuticals position peaked at $812K in Q2 2018.
  • 218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Oppenheimer Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.